2018
Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort
Okeke NL, Alenezi F, Bloomfield GS, Dunning A, Clement ME, Shah SH, Naggie S, Velazquez EJ. Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort. Journal Of Cardiac Failure 2018, 24: 496-503. PMID: 29964194, PMCID: PMC6231907, DOI: 10.1016/j.cardfail.2018.06.003.Peer-Reviewed Original ResearchConceptsLeft ventricular hypertrophyDiastolic dysfunctionTransthoracic echocardiogramVentricular hypertrophyHuman immunodeficiency virus-infected personsDuke University Medical CenterDefinite diastolic dysfunctionHIV Clinical CohortStructural myocardial abnormalitiesVirus-infected personsHuman immunodeficiency virusCells/University Medical CenterCD4 nadirsCD4 countViral suppressionPrimary outcomeImmune suppressionImmunodeficiency virusMyocardial abnormalitiesClinical cohortMedical CenterHigh riskImmune functionInfected persons
2008
Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction The VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study
Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, Velazquez EJ, McMurray JJ, Kober L, Pfeffer MA, Califf RM, Solomon SD. Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction The VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovascular Imaging 2008, 1: 582-591. PMID: 19356485, DOI: 10.1016/j.jcmg.2008.05.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersCardiovascular DiseasesEuropeFemaleHeart VentriclesHumansHypertrophy, Left VentricularKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPredictive Value of TestsProportional Hazards ModelsRecurrenceRisk AssessmentRisk FactorsTetrazolesTime FactorsTreatment OutcomeUltrasonographyUnited StatesValineValsartanVentricular RemodelingConceptsLeft ventricular mass indexRelative wall thicknessHigh-risk myocardial infarctionAdverse cardiovascular eventsLeft ventricular massMyocardial infarctionLV geometryCardiovascular eventsConcentric remodelingEchocardiographic studyLV hypertrophyConcentric hypertrophyEccentric hypertrophyPrognostic implicationsVentricular massBaseline left ventricular mass indexMean left ventricular mass indexBaseline left ventricular massHigher relative wall thicknessBaseline LV massNonfatal cardiovascular outcomesAbnormal LV geometryComposite end pointVentricular mass indexConcentric LV hypertrophy
2005
Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction
Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA. Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction. Circulation 2005, 111: 3411-3419. PMID: 15967846, DOI: 10.1161/circulationaha.104.508093.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin-Converting Enzyme InhibitorsCaptoprilDrug Therapy, CombinationElectrocardiographyFemaleHeart VentriclesHospitalizationHumansHypertrophy, Left VentricularMaleMiddle AgedMyocardial InfarctionPrognosisStroke VolumeTetrazolesTreatment OutcomeValineValsartanVentricular Dysfunction, LeftConceptsAngiotensin receptor blockersMyocardial infarctionEjection fractionEchocardiographic measuresPo bidPo tidHeart failureTreatment armsInfarct segment lengthProgressive LV enlargementVALIANT Echo studyLV ejection fractionLeft ventricular enlargementCombination of captoprilACE inhibitor captoprilEnd-diastolic volumeARB valsartanEchocardiographic characteristicsVALIANT studyCardiovascular eventsEchocardiographic parametersLV dysfunctionReceptor blockersLV enlargementVentricular enlargement